May 1, 2022
New specialty pharmacy medical step therapy requirements
Effective March 1, 2022, the following Part B medications from the current Clinical Utilization Management (UM) Guidelines will be included in our medical step therapy precertification review process. Step therapy review will apply upon precertification initiation, in addition to the current medical necessity review (as is current procedure). Step therapy will not apply for members who are actively receiving medications listed below.
Clinical UM Guidelines are publicly available on the provider website. Visit the Clinical Criteria page to search for specific criteria.
Clinical UM Guidelines |
Preferred drug(s) |
Nonpreferred drug(s) |
· ING-CC-0062 |
· Inflectra · Remicade, Infliximab (unbranded) |
· Avsola · Renflexis |
PUBLICATIONS: May 2022 Anthem Blue Cross Provider News - California
To view this article online:
Or scan this QR code with your phone